GLP-1s & Weight Loss

Semaglutide

Educational research reference. This page was restored from the structured compound dataset included with this site export. Protocol examples are context for review and are not medical advice.

At a glance

Route(s)

Subcutaneous

Target

GLP-1

Timing window

Anytime

Regulatory status

approved drug label available

Protocol context

Standard Protocol

Timeframe	Dose / exposure	Notes
Weeks 1-4	0.25mg once weekly	Initiation phase. Essential to build GI tolerance.
Weeks 5-8	0.5mg once weekly	First escalation phase.
Weeks 9-12	1.0mg once weekly	Standard therapeutic threshold.
Weeks 13-16	1.7mg once weekly	Advanced weight loss phase.
Weeks 17+	2.4mg once weekly	Maximum clinical research dose.

Alternative: Split Dosing

Timeframe	Dose / exposure	Notes
Weeks 1-4	0.125mg every 3.5 days	E.g., Monday AM and Thursday PM. Flattens plasma levels to reduce nausea.
Weeks 5-8	0.25mg every 3.5 days	Equals 0.5mg weekly.
Weeks 9-12	0.5mg every 3.5 days	Equals 1.0mg weekly.
Weeks 13+	0.85mg every 3.5 days	Equals 1.7mg weekly.

Alternative: Daily Micro-Dosing

Timeframe	Dose / exposure	Notes
Weeks 1-4	0.035mg daily	Daily subQ injections completely stabilize peaks and valleys, virtually eliminating all GI side effects.
Weeks 5-8	0.07mg daily	Equals ~0.5mg weekly.
Weeks 9+	0.14mg daily	Equals ~1.0mg weekly. Adjust upward based on appetite suppression.

Protocol logic

Weight-loss protocols should not pretend fat loss is only willpower. The logic is appetite signaling, GI tolerance, adherence, protein, resistance training, hydration, and preserving lean mass while the dose changes. Entry context: target (GLP-1); route Subcutaneous; timing Anytime. Label/trial anchors carry more weight than forum-style escalation. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. Common diet-myth context matters: rapid vs slow loss is individual, fasting only helps when adherence improves, and protein/training protect lean mass during aggressive deficits.

Side effects / cautions listed in dataset

Nausea: most prevalent adverse effect; reported in up to 44% of subjects at higher doses.
Vomiting.
Diarrhea.
Constipation.
Abdominal pain and cramping.
Dyspepsia (indigestion).
Abdominal distension and bloating.
Decreased appetite and dysgeusia (altered taste).
Belching and flatulence.
Gastroparesis: delayed gastric emptying that may persist even with pre-operative fasting.
Gastroesophageal reflux disease (GERD) exacerbation.
Fatigue and lethargy: frequently secondary to acute caloric deficit rather than direct drug toxicity.
Headache.
Dizziness.
Hypoglycemia: risk significantly elevated when combined with insulin, sulfonylureas, or other glucose-lowering agents.
Acute pancreatitis: documented in case reports and clinical trials.
Acute kidney injury: primarily mediated by dehydration from GI side effects.
Cholelithiasis (gallstones) and acute cholecystitis: risk increases with dose and duration.
Diabetic retinopathy complications: risk elevated in subjects with pre-existing retinopathy during rapid glycemic correction.
Nonarteritic anterior ischemic optic neuropathy (NAION): reported in post-marketing and retrospective cohort data; causality not confirmed.
Thyroid C-cell tumor risk: confirmed in rodent models; human risk unclear; monitor for neck mass, hoarseness, or dysphagia.
Alopecia (hair loss): reported in post-marketing surveillance.
Injection site reactions: redness, itching, bruising at administration site.
Anaphylaxis and angioedema: rare but documented.
Pulmonary aspiration risk under general anesthesia: secondary to delayed gastric emptying.
Rapid weight regain upon discontinuation: approximately two-thirds of lost weight regained within one year without lifestyle maintenance.

Contraindications / risk flags listed in dataset

Personal or family history of Medullary Thyroid Carcinoma (MTC).
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Personal or family history of thyroid C-cell tumors.
Active or history of acute pancreatitis.
Type 1 diabetes mellitus.
Diabetic ketoacidosis.
Severe gastroparesis or clinically significant delayed gastric emptying.
Pregnancy: manufacturer advises discontinuation at least 2 months prior to planned conception due to potential fetal risk.
Breastfeeding: insufficient safety data; potential risk of transfer to infant.
Known hypersensitivity or anaphylaxis to semaglutide or any formulation excipient.
Concurrent use with other GLP-1 receptor agonists (e.g., liraglutide, dulaglutide, exenatide): overlapping mechanism with additive adverse effects.
Concurrent use with tirzepatide, retatrutide, or any dual/triple incretin agonist: direct pharmacological conflict.
History of suicidal ideation or prior suicide attempts: monitor closely.
Planned general anesthesia or elective surgery: delayed gastric emptying raises risk of pulmonary aspiration; follow pre-operative fasting protocols.
Pediatric use under age 12: safety and efficacy not established.
End-stage renal disease on dialysis: limited clinical evidence; use with extreme caution.

Related compounds

Synergistic / related

Cagrilintide AOD-9604 Tesofensine